AUTHOR=Dong Xuan , Meng Fanfeng , Hu Tao , Ju Sidi , Li Yang , Sun Peng , Wang Yixin , Chen Wenqing , Zhang Fushou , Su Hongqin , Li Sifei , Cui He , Chen Junxia , Xu Shuzhen , Fang Lichun , Luan Huaibiao , Zhang Zhenjie , Chang Shuang , Li Jianliang , Wang Lei , Zhao Peng , Shi Weifeng , Cui Zhizhong TITLE=Dynamic Co-evolution and Interaction of Avian Leukosis Virus Genetic Variants and Host Immune Responses JOURNAL=Frontiers in Microbiology VOLUME=8 YEAR=2017 URL=https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2017.01168 DOI=10.3389/fmicb.2017.01168 ISSN=1664-302X ABSTRACT=

Subgroup J avian leukosis virus (ALV-J), a typical retrovirus, is characterized of existence of a cloud of diverse variants and considerable genetic diversity. Previous studies describing the evolutionary dynamics of ALV-J genetic variants mainly focused on the early infection period or few randomly selected clones. Here, we inoculated 30 specific-pathogen-free chickens with the same founder ALV-J stock of known genetic background. Six (three antibody positive and three antibody negative) chickens were selected among 15 chickens with viremia. Viruses were serially isolated in 36 weeks and then sequenced using MiSeq high-throughput sequencing platform. This produced the largest ALV-J dataset to date, composed of more than three million clean reads. Our results showed that host humoral immunity could greatly enhance the genetic diversity of ALV-J genetic variants. In particular, selection pressures promoted a dynamic proportional changes in ALV-J genetic variants frequency. Cross-neutralization experiment showed that along with the change of the dominant variant, the antibody titers specific to infectious clones corresponding to the most dominant variants in weeks 12 and 28 have also changed significantly in sera collected in weeks 16 and 32. In contrast, no shift of dominant variant was observed in antibody-negative chickens. Moreover, we identified a novel hypervariable region in the gp85 gene. Our study reveals the interaction between ALV-J and the host, which could facilitate the development of vaccines and antiviral drugs.